Injection of CD4 and CD8 + T Cells Anti-Cytomegalovirus (CMV) or Anti-adenovirus

Cytomegalovirus Infections Clinical Trial

— CTLantiCMV  

Official title:

Injection of CD4 and CD8 + T Cells Anti-CMV or Anti-adenovirus for the Treatment of Viral Infections Occurring After Allogenic Hematopoietic Stem Cell Transplantation (HSCT)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01325636
• Other study ID #: P090801
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: March 28, 2011
• Last updated: April 9, 2015
• Start date: September 2010
• Est. completion date: May 2014

Study information

• Verified date: June 2014
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

The main purpose of this project is to evaluate the efficiency of the injection of CD4 and CD8+ T cell anti-Cytomegalovirus (CMV) on blood viral replication of CMV, 21 days after the first injection (adenovirus infection is not enough usual, especially in adults, to be used for the primary purpose and is measured in the secondary endpoints).

Description:

Cytomegalovirus (CMV) and adenoviruses infections are a major source of morbidity and mortality after allogenic haematopoietic stem cell transplantation (HSC). Conventional antiviral therapy have sometimes insufficient efficiency and a significant potential toxicity. Over the last ten years, adoptive immunotherapy has demonstrated its efficiency in treatment of viral infections in this context. Different methods have been used but organizational and technological barriers have prevented a wide use of this therapeutic approach.

This protocol aims to assess the efficiency of treatment by injection of donor CD4 + and CD8 + T cells specifically directed against cytomegalovirus or adenovirus, to patients receiving allogenic transplant with infection of one of these two viruses, and in conventional antiviral treatment failure. Donor memory T cells will be obtained from an aphaeresis of mononuclear cells and will be selected on the basis of their ability to produce interferon-gamma (IFN-g) after stimulation with viral peptides. The speed (48 hours) and the reproducibility of this method let hope a better feasibility for clinical use compared to previously developed technologies. Given epidemiology different after allogenic transplant of HSC of these two viruses, and the relative low expected number of patients with adenovirus infection, statistical analysis will focus exclusively on patients who received T cells for CMV infection. The study of efficiency and tolerance of this adoptive immunotherapy for adenovirus will be considered as a secondary purpose.

This is a multicenter non-comparative phase I/II protocol, which predicts the inclusion of 30 patients with 25 patients infected with CMV, to demonstrate efficiency of 55% with a minimum required efficiency of 30%, an alpha risk of 10% and a strength of 90%. The main purpose of the study is to evaluate the efficiency of this treatment on the level of CMV viral replication 21 days after the first injection. A positive response is defined by a viral load became undetectable or reduced by at least 2 log10. A negative response is defined on the basis of unchanged or increased viral load after injection of T cells; a partial response is defined as a significant decrease (greater than 0.3log10 copies / ml but less than 2 log10) of the viral load, which still remains above the detection threshold. For patients with an isolated organ damage (patient without PCR), a positive response is defined by the healing of the affected organ. In case of negative or partial response 21 days after the first injection, a second injection if available can be programmed in the absence of clinical signs of graft versus host or aggravation of pre-existing GVHa. The secondary purposes are: a) assess the tolerance, in terms of occurrence of acute reaction graft versus host (GVHa) directly due to the injection of T cells ; b) evaluation of indirect biological parameters of efficiency such as injected T cells expansion studied using tetramers specific secretion of IFN-g; c) the study of efficiency and tolerance of this immunotherapy against adenovirus. Inclusion criteria concern children and adults who have received allogenic transplant of HSC, which donor is CMV + and having an active viral infection: 1) in conventional antiviral treatment failure, with a persistent viral load and/or increased after 15 days of treatment or with CMV or ADV disease with organ damage documented without systemic replication (if possible, with a CMV PCR or ADV PCR positive in the organ), or 2) in intolerance or toxicity situation of this treatment which prevents its pursuit. Donor T cells will be injected if the following conditions are observed : 1) donor chimerism > 10%, 2) absence of GvHa ≥ grade II 3) absence of severe organ failure. The antiviral drug therapy may eventually be continued jointly with cellular immunotherapy.

Number of participating centers: grafter centers of Ile-de-France and Hospital Edouard HERRIOT to Lyon, CHU of Nantes, CHU of Poitiers (so 10 centers). The study duration will be 42 months, with an inclusion period of 36 months and a follow-up period of 6 months from the last inclusion. If the study gives expected results, a compared phase III trial will be considered for the treatment of CMV infections and a Phase I/II for the treatment of adenoviral infection.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: May 2014
• Est. primary completion date: January 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Child or adult patient (without age limit) treated by allogenic haematopoietic stem cell transplant whatever underlying pathology with a donor chimerism = 10 %, at the time of the inclusion and :

• having biological signs (blood viral load) associated or not with clinical signs of infection by CMV and / or resistant or intolerant Adenovirus (myelotoxicity or nephrotoxicity) to a conventional antiviral treatment

• or with CMV or ADV disease with organ damage documented without systemic replication (if possible, with a CMV PCR or ADV PCR positive in the organ)

• without GvHa at the time of the inclusion or GvHa = II controlled by Corticoids < 1mg / Kg (but corticosteroids on decrease) or cyclosporine only. A possible treatment by monoclonal antibody anti r-IL2 (LEUCOTAC) must have been interrupted for at least 8 days. The preventive treatment of the GvHa by cyclosporine or mycophenolate mofetil is compatible with the study

• answering to eligibility criteria for the donor (in particular donor CMV positive serology and absence of intercurrent infections)

• having been informed - he or his legal representative - and having signed the informed consent

• patient member or benefiting from a social security scheme

Exclusion Criteria:

• donor CMV negative serology (in the case of anti-CMV immunotherapy). Note : all donors are considered as having met the adenovirus and the status serology towards this virus, will not be checked.

• GvHa > II and/or requiring a corticosteroid therapy > 0,5 mg/kg/day and/or a treatment by monoclonal antibody anti-rIl2 could not be interrupted or other immunosuppressor treatment which could potentially interfere with the survival of injected T cell (Thymoglobuline, Campath etc)

• severe organ failure involving the patient's vital prognostic in the short term

• rejection of sample from the donor

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Adenoviridae Infections
• Adenovirus Infections
• Communicable Diseases
• Cytomegalovirus Infections
• Infection

Intervention

Other:
• Cell therapy
Injection of specific T cell by intravenous way with a posology of 1000 to 5000 CD3 IFN ?+ / kg. A second injection could be made at day 21

Locations

Country	Name	City	State
France	Biotherapy department, Hôpital Necker - Enfants Malades	Paris Cedex 15

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	CMV blood viral load by PCR		at day 21	No
Secondary	GvHa evaluation		at week 1, 2 ,3 ,4 and at month 1, 2, 3, 4, 5, 6	Yes
Secondary	Evaluation of clinical signs according to interested organs (lung, liver, bowel,…)		at week 1, 2 ,3 ,4 and at month 1, 2, 3, 4, 5, 6	No
Secondary	Increase of T cells		at week 1, 2 ,3 ,4, 6, 8, 10, 12 and at month 3, 4, 5, 6	No